FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087667054> ?p ?o ?g. }

• W2087667054 endingPage "e33" @default.
• W2087667054 startingPage "e33" @default.
• W2087667054 abstract "Many malaria vaccines are currently in development, although very few have been evaluated for efficacy in the field. Plasmodium falciparum multiple epitope (ME)- thrombospondin-related adhesion protein (TRAP) candidate vaccines are designed to potently induce effector T cells and so are a departure from earlier malaria vaccines evaluated in the field in terms of their mechanism of action. ME-TRAP vaccines encode a polyepitope string and the TRAP sporozoite antigen. Two vaccine vectors encoding ME-TRAP, plasmid DNA and modified vaccinia virus Ankara (MVA), when used sequentially in a prime-boost immunisation regime, induce high frequencies of effector T cells and partial protection, manifest as delay in time to parasitaemia, in a clinical challenge model.A total of 372 Gambian men aged 15-45 y were randomised to receive either DNA ME-TRAP followed by MVA ME-TRAP or rabies vaccine (control). Of these men, 296 received three doses of vaccine timed to coincide with the beginning of the transmission season (141 in the DNA/MVA group and 155 in the rabies group) and were followed up. Volunteers were given sulphadoxine/pyrimethamine 2 wk before the final vaccination. Blood smears were collected weekly for 11 wk and whenever a volunteer developed symptoms compatible with malaria during the transmission season. The primary endpoint was time to first infection with asexual P. falciparum. Analysis was per protocol. DNA ME-TRAP and MVA ME-TRAP were safe and well-tolerated. Effector T cell responses to a non-vaccine strain of TRAP were 50-fold higher postvaccination in the malaria vaccine group than in the rabies vaccine group. Vaccine efficacy, adjusted for confounding factors, was 10.3% (95% confidence interval, -22% to +34%; p = 0.49). Incidence of malaria infection decreased with increasing age and was associated with ethnicity.DNA/MVA heterologous prime-boost vaccination is safe and highly immunogenic for effector T cell induction in a malaria-endemic area. But despite having produced a substantial reduction in liver-stage parasites in challenge studies of non-immune volunteers, this first generation T cell-inducing vaccine was ineffective at reducing the natural infection rate in semi-immune African adults." @default.
• W2087667054 created "2016-06-24" @default.
• W2087667054 creator A5027270405 @default.
• W2087667054 creator A5044222247 @default.
• W2087667054 creator A5045727353 @default.
• W2087667054 creator A5045818580 @default.
• W2087667054 creator A5047388405 @default.
• W2087667054 creator A5051592498 @default.
• W2087667054 creator A5057807377 @default.
• W2087667054 creator A5058236091 @default.
• W2087667054 creator A5059924108 @default.
• W2087667054 creator A5065001698 @default.
• W2087667054 creator A5078644517 @default.
• W2087667054 date "2004-10-26" @default.
• W2087667054 modified "2023-09-27" @default.
• W2087667054 title "A Randomised, Double-Blind, Controlled Vaccine Efficacy Trial of DNA/MVA ME-TRAP Against Malaria Infection in Gambian Adults" @default.
• W2087667054 cites W1536233937 @default.
• W2087667054 cites W1589948634 @default.
• W2087667054 cites W1808985647 @default.
• W2087667054 cites W1987106815 @default.
• W2087667054 cites W1988952151 @default.
• W2087667054 cites W1997488133 @default.
• W2087667054 cites W2001659332 @default.
• W2087667054 cites W2004979064 @default.
• W2087667054 cites W2016794123 @default.
• W2087667054 cites W2036497142 @default.
• W2087667054 cites W2042094287 @default.
• W2087667054 cites W2045377848 @default.
• W2087667054 cites W2046182783 @default.
• W2087667054 cites W2051108441 @default.
• W2087667054 cites W2062096354 @default.
• W2087667054 cites W2065795429 @default.
• W2087667054 cites W2070457810 @default.
• W2087667054 cites W2074122062 @default.
• W2087667054 cites W2075533042 @default.
• W2087667054 cites W2075817888 @default.
• W2087667054 cites W2081139134 @default.
• W2087667054 cites W2090020022 @default.
• W2087667054 cites W2095135796 @default.
• W2087667054 cites W2118599971 @default.
• W2087667054 cites W2121713659 @default.
• W2087667054 cites W2127344303 @default.
• W2087667054 cites W2130083941 @default.
• W2087667054 cites W2131815077 @default.
• W2087667054 cites W2134502530 @default.
• W2087667054 cites W2137225997 @default.
• W2087667054 cites W2139189726 @default.
• W2087667054 cites W2139338343 @default.
• W2087667054 cites W2141603824 @default.
• W2087667054 cites W2147862160 @default.
• W2087667054 cites W2149791183 @default.
• W2087667054 cites W2151597897 @default.
• W2087667054 cites W2155144810 @default.
• W2087667054 cites W2169945363 @default.
• W2087667054 cites W2868963225 @default.
• W2087667054 cites W4379364173 @default.
• W2087667054 doi "https://doi.org/10.1371/journal.pmed.0010033" @default.
• W2087667054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/524376" @default.
• W2087667054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15526058" @default.
• W2087667054 hasPublicationYear "2004" @default.
• W2087667054 type Work @default.
• W2087667054 sameAs 2087667054 @default.
• W2087667054 citedByCount "169" @default.
• W2087667054 countsByYear W20876670542012 @default.
• W2087667054 countsByYear W20876670542013 @default.
• W2087667054 countsByYear W20876670542014 @default.
• W2087667054 countsByYear W20876670542015 @default.
• W2087667054 countsByYear W20876670542016 @default.
• W2087667054 countsByYear W20876670542017 @default.
• W2087667054 countsByYear W20876670542018 @default.
• W2087667054 countsByYear W20876670542019 @default.
• W2087667054 countsByYear W20876670542020 @default.
• W2087667054 countsByYear W20876670542021 @default.
• W2087667054 countsByYear W20876670542022 @default.
• W2087667054 crossrefType "journal-article" @default.
• W2087667054 hasAuthorship W2087667054A5027270405 @default.
• W2087667054 hasAuthorship W2087667054A5044222247 @default.
• W2087667054 hasAuthorship W2087667054A5045727353 @default.
• W2087667054 hasAuthorship W2087667054A5045818580 @default.
• W2087667054 hasAuthorship W2087667054A5047388405 @default.
• W2087667054 hasAuthorship W2087667054A5051592498 @default.
• W2087667054 hasAuthorship W2087667054A5057807377 @default.
• W2087667054 hasAuthorship W2087667054A5058236091 @default.
• W2087667054 hasAuthorship W2087667054A5059924108 @default.
• W2087667054 hasAuthorship W2087667054A5065001698 @default.
• W2087667054 hasAuthorship W2087667054A5078644517 @default.
• W2087667054 hasBestOaLocation W20876670541 @default.
• W2087667054 hasConcept C104317684 @default.
• W2087667054 hasConcept C159047783 @default.
• W2087667054 hasConcept C159654299 @default.
• W2087667054 hasConcept C167508917 @default.
• W2087667054 hasConcept C203014093 @default.
• W2087667054 hasConcept C22070199 @default.
• W2087667054 hasConcept C2522874641 @default.
• W2087667054 hasConcept C2777760223 @default.
• W2087667054 hasConcept C2777961786 @default.
• W2087667054 hasConcept C2778048844 @default.
• W2087667054 hasConcept C2778371730 @default.

• next